|
87
|
294
|
6rfiA |
Irak4 in complex with inhibitor |
|
92
|
291
|
6in0A |
Crystal structure of epha3 in complex with 18-crown-6 |
|
91
|
299
|
6iupA |
Crystal structure of fgfr4 kinase domain in complex with compound 5 |
|
88
|
289
|
6nvhA |
Fgfr4 complex with n-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide |
|
85
|
289
|
6nviA |
Fgfr4 complex with n-(3-chloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-5-fluorophenyl)acrylamide |
|
83
|
303
|
6nvlA |
Fgfr1 complex with n-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide |
|
86
|
290
|
6nvjA |
Fgfr4 complex with n-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-fluorophenyl)acrylamide |
|
85
|
290
|
6nvgA |
Fgfr4 complex with n-(3,5-dichloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)phenyl)acrylamide |
|
81
|
289
|
6nvkA |
Fgfr4 complex with blu-554, n-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2h-pyran-4-yl)acrylamide |
|
99
|
307
|
6mweA |
Crystal structure of tie2 in complex with decipera compound dp1919 |
|
86
|
269
|
6hm6A |
Crystal structure of spleen tyrosine kinase (syk) in complex with a 2-(pyridinyloxymethyl)pyridine inhibitor |
|
89
|
306
|
6hmxA |
Rip2 kinase catalytic domain complex with n(4,5dimethyl1hpyrazol3yl)7methoxy6(2methylpropane2sulfonyl)quinolin4amine |
|
89
|
271
|
6hm7A |
Crystal structure of spleen tyrosine kinase (syk) in complex with a 2-(phenoxymethyl)pyridine inhibitor |
|
81
|
270
|
6mibA |
Crystal structure of the ilk atp-binding deficient mutant (l207w)/alpha-parvin core complex |
|
90
|
288
|
6hd4A |
Abl1 in complex with compound 7 and imatinib (sti-571) |
|
86
|
299
|
6ferA |
Crystal structure of human ddr2 kinase in complex with 2-[4,5-difluoro-2-oxo-1'-(1h-pyrazolo[3,4-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-n-(2,2,2-trifluoroethyl)acetamide |
|
94
|
303
|
6fimA |
Ddr1, 2-[8-(1h-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-n-methylacetamide, 1.440a, p1211, rfree=24.1% |
|
90
|
301
|
6elrA |
Human jak1 kinase domain in complex with compound 7 |
|
86
|
287
|
6dudA |
Jak3 with cyanamide cp12 |
|
92
|
303
|
6finA |
Ddr1, 3-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-8-(1h-indazole-5-carbonyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, 1.670a, p1211, rfree=22.8% |
|
87
|
287
|
6db4A |
Jak3 with cyanamide cp34 |
|
92
|
271
|
6di0A |
Crystal structure of btk in complex with fragment ligand |
|
99
|
309
|
6fioA |
Ddr1, 2-[1'-(1h-indazole-5-carbonyl)-4-methyl-2-oxospiro[indole-3,4'-piperidine]-1-yl]-n-(2,2,2-trifluoroethyl)acetamide, 1.990a, p6522, rfree=27.7% |
|
84
|
285
|
6da4A |
Jak3 with cyanamide cp10 |
|
95
|
307
|
6fiqA |
Ddr1, 1-(1h-indazole-5-carbonyl)-5'-methoxy-1'-[2-oxo-2-[(2s)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl]spiro[piperidine-4,3'-pyrrolo[3,2-b]pyridine]-2'-one, 1.790a, p212121, rfree=23.8% |
|
93
|
301
|
6fexA |
Ddr1, 2-[4-bromo-2-oxo-1'-(1h-pyrazolo[4,3-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-n-(2,2,2-trifluoroethyl)acetamide, 1.291a, p212121, rfree=17.4% |
|
91
|
271
|
6di1A |
Crystal structure of btk in complex with covalent fragment ligand |
|
95
|
303
|
6filA |
Ddr1, 2-[8-(1h-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-n-methylacetamide, 1.730a, p212121, rfree=24.5% |
|
84
|
287
|
6db3A |
Jak3 with cyanamide cp23 |
|
94
|
303
|
6fewA |
Ddr1, 2-[8-(1h-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-n-methylacetamide, 1.440a, p1211, rfree=24.1% |
|
87
|
264
|
6blnA |
Btk complex with compound 13 |
|
88
|
266
|
6bkwA |
Btk complex with compound 12 |
|
87
|
263
|
6bkhA |
Btk complex with compound 11 |
|
91
|
309
|
6brjA |
Ddr1 bound to vx-680 |
|
92
|
309
|
6bsdA |
Ddr1 bound to dasatinib |
|
86
|
264
|
6bikA |
Btk complex with compound 7 |
|
82
|
264
|
6bkeA |
Btk complex with compound 10 |
|
86
|
269
|
6npuA |
C-abl kinase domain with the activator(cmpd29), n-(1-(3,4-dichlorophenyl)-4,5-dihydro-1h-pyrazol-3-yl)acetamide |
|
88
|
269
|
6npeA |
C-abl kinase domain with the activator(cmpd6), 2-cyano-n-(4-(3,4-dichlorophenyl)thiazol-2-yl)acetamide |
|
88
|
269
|
6npvA |
C-abl kinase domain with the activator(cmpd51), n-(1-(3,4-dichlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1h-pyrazol-3-yl)isonicotinamide |
|
100
|
302
|
5qinA |
Tgf-beta receptor type 2 kinase domain in complex with n- {4-[3-(6-methoxypyridin-3-yl)-1h-pyrrolo[3,2-b]pyridin-2- yl]pyridin-2-yl}acetamide |
|
89
|
271
|
6n9pA |
Discovery of affinity-based probes for btk occupancy assay |
|
79
|
268
|
6nfiA |
Btk in complex with inhibitor n-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazol-6-yl)methanesulfonamide |
|
90
|
271
|
6nfhA |
Btk in complex with inhibitor 8-(2,3-dihydro-1h-inden-5-yl)-2-({4-[(2s)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8-dihydropteridine-6,7-dione |
|
94
|
307
|
6mx8A |
Crystal structure of anaplastic lymphoma kinase (alk) bound by brigatinib |
|
85
|
302
|
6mzqA |
Tas-120 in reversible binding mode with fgfr1 |
|
84
|
275
|
6i8zA |
Crystal structure of ptk2 in complex with bi-4464. |
|
77
|
262
|
6mnyA |
Crystal structure of mouse btk kinase domain in complex with compound 9a |
|
83
|
302
|
6mzwA |
Tas-120 covalent complex with fgfr1 |
|
100
|
296
|
6n8gA |
Irak4 bound to benzoxazole compound |
